CRMD

CorMedix Inc

Add to Watchlist

Advanced Chart

12.280

+0.590(+5.050%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

12.330

Open

11.650

VWAP

12.15

Vol

1.42M

Mkt Cap

832.89M

Low

11.650

Amount

17.30M

EV/EBITDA(TTM)

47.94

Total Shares

54.96M

715.37M

EV/OCF(TTM)

P/S(TTM)

8.74

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

35.75M

+212.07%

29.88M

+3606.46%

Estimates Revision

The market is revising Upward the revenue expectations for CorMedix Inc. (CRMD) for FY2025, with the revenue forecasts being adjusted by 10.76% over the past three months. During the same period, the stock price has changed by 15.52%.

Revenue Estimates for FY2025

Revise Upward

+10.76%

In Past 3 Month

Stock Price

Go Up

+15.52%

In Past 3 Month

6 Analyst Rating

41.12% Upside

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 17.33 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

41.12% Upside

Current: 12.280

Low

12.00

Averages

17.33

High

20.00

41.12% Upside

Current: 12.280

Low

12.00

Averages

17.33

High

20.00

Needham

Serge Belanger

Strong Buy

Reiterates

$12

2025-04-09

Reason

Needham

Serge Belanger

Price Target

$12

2025-04-09

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$15

2025-04-08

Reason

D. Boral Capital

Jason Kolbert

Price Target

$15

2025-04-08

Maintains

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Maintains

$18 → $12

2025-03-26

Reason

Needham

Serge Belanger

Price Target

$18 → $12

2025-03-26

Maintains

Strong Buy

Reason

RBC Capital

Gregory Renza

Buy

Reiterates

$12

2025-03-26

Reason

RBC Capital

Gregory Renza

Price Target

$12

2025-03-26

Reiterates

Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$15

2025-03-25

Reason

D. Boral Capital

Jason Kolbert

Price Target

$15

2025-03-25

Maintains

Strong Buy

Reason

Leerink Partners

Roanna Ruiz

Buy

Initiates

$18

2025-03-07

Reason

Leerink Partners

Roanna Ruiz

Price Target

$18

2025-03-07

Initiates

Buy

Reason

Leerink analyst Roanna Ruiz initiated coverage of CorMedix with an Outperform rating and $18 price target. The firm believes the company's lead product DefenCath represents a significant advancement in catheter-related bloodstream infection prevention with demonstrated up to 70% reduction in infection rates, positioning it well to address a critical unmet need in hemodialysis patients. Leerink forecasts about $370M peak non-risk adjusted sales for its current indication in 2028. Further, robust gross margins, early favorable TDAPA and NTAP reimbursement in outpatient and inpatient settings, and a possible uptake boost from a real-world evidence study on hospitalization and mortality rates could support durable DefenCath revenue generation. Multiple label expansion opportunities could at least double DefenCath's addressable market, Leerink adds.

See All Ratings

Valuation Metrics

The current forward P/E ratio for CorMedix Inc (CRMD.O) is 14.43, compared to its 5-year average forward P/E of -6.39. For a more detailed relative valuation and DCF analysis to assess CorMedix Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.39

Current PE

14.43

Overvalued PE

33.81

Undervalued PE

-46.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.07

Current EV/EBITDA

7.37

Overvalued EV/EBITDA

7.41

Undervalued EV/EBITDA

-7.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4126.34

Current PS

5.07

Overvalued PS

18243.17

Undervalued PS

-9990.48